Chris P. Recknor - 31 Mar 2022 Form 4 Insider Report for CytoDyn Inc. (CYDY)

Role
Officer
Signature
/s/ Antonio Migliarese, Attorney-In-Fact
Issuer symbol
CYDY
Transactions as of
31 Mar 2022
Net transactions value
$0
Form type
4
Filing time
08 Jun 2022, 16:06:27 UTC
Previous filing
10 Aug 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CYDY Common Stock Award $0 +12,950 +1.9% $0.000000 699,000 31 Mar 2022 Direct F1
transaction CYDY Common Stock Award $0 +17,746 +2.5% $0.000000 716,746 15 Apr 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Chris P. Recknor is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary.

Remarks:

Sr. VP Clinical Operations, Dr Chris P. Recknor served in the position of Sr. VP Clinical Operations until 4/19/2022. EX 24 - Power of Attorney